82 related articles for article (PubMed ID: 15303247)
1. The efficiency of a carbamazepine-mianserin combination scheme in opiate detoxification.
Zullino DF; Krenz S; Favrat B; Zimmermann G; Bertschy G; Besson J
Hum Psychopharmacol; 2004 Aug; 19(6):425-30. PubMed ID: 15303247
[TBL] [Abstract][Full Text] [Related]
2. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program--a randomized, double blind, placebo controlled, prospective study.
Herman I; Shamir D; Bar-Hamburger R; Pick CG; Schreiber S
Addict Behav; 2005 Jul; 30(6):1154-67. PubMed ID: 15925125
[TBL] [Abstract][Full Text] [Related]
3. The association carbamazepine-mianserin in opiate withdrawal: a double blind pilot study versus clonidine.
Bertschy G; Bryois C; Bondolfi G; Velardi A; Budry P; Dascal D; Martinet C; Baettig D; Baumann P
Pharmacol Res; 1997 May; 35(5):451-6. PubMed ID: 9308074
[TBL] [Abstract][Full Text] [Related]
4. Topiramate in opiate withdrawal- comparison with clonidine and with carbamazepine/mianserin.
Zullino DF; Krenz S; Zimmerman G; Miozzari A; Rajeswaran R; Kolly S; Khazaal Y
Subst Abus; 2004 Dec; 25(4):27-33. PubMed ID: 16172090
[TBL] [Abstract][Full Text] [Related]
5. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
[TBL] [Abstract][Full Text] [Related]
6. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
[TBL] [Abstract][Full Text] [Related]
7. [Carbamazepine in the treatment in psychiatric disorders based on retrospective clinical study].
Afeltowicz Z; Majkowicz M; Michalik K; Radziwiłłowicz P; Sowiński P; Smoczyński S; Trzebiatowska IA
Psychiatr Pol; 2002; 36(6 Suppl):303-10. PubMed ID: 12647453
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study.
Zhang ZJ; Kang WH; Tan QR; Li Q; Gao CG; Zhang FG; Wang HH; Ma XC; Chen C; Wang W; Guo L; Zhang YH; Yang XB; Yang GD
J Psychiatr Res; 2007; 41(3-4):360-9. PubMed ID: 16081106
[TBL] [Abstract][Full Text] [Related]
9. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
[TBL] [Abstract][Full Text] [Related]
10. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
11. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
Malhi GS; Ng F; Berk M
Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence.
Soyka M; Schmidt F; Schmidt P
Pharmacopsychiatry; 2006 Jan; 39(1):30-4. PubMed ID: 16453252
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
14. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Pasquini M; Biondi M; Costantini A; Cairoli F; Ferrarese G; Picardi A; Sternberg C
Depress Anxiety; 2006; 23(7):441-8. PubMed ID: 16841345
[TBL] [Abstract][Full Text] [Related]
15. [Detoxification of poly-substance abusers with buprenorphine. Effects on affect, anxiety, and withdrawal symptoms].
Paetzold W; Eronat V; Seifert J; Holze I; Emrich HM; Schneider U
Nervenarzt; 2000 Sep; 71(9):722-9. PubMed ID: 11042867
[TBL] [Abstract][Full Text] [Related]
16. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome.
Janiri L; Martinotti G; Tonioni F; Ghelardini C; Nicolai R; Galeotti N; Mosconi L; Calvani M; Bartolini A; Iannoni E
Clin Neuropharmacol; 2009; 32(1):35-40. PubMed ID: 18978503
[TBL] [Abstract][Full Text] [Related]
17. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification.
Liappas J; Paparrigopoulos T; Tzavellas E; Rabavilas A
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):55-60. PubMed ID: 15610945
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.
Hannan N; Hamzah Z; Akinpeloye HO; Meagher D
J Psychopharmacol; 2007 Mar; 21(2):161-4. PubMed ID: 17329295
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
